Next, a one-way ANOVA of repeated measures revealed a significant decrease in YKL-40 plasma levels in nusinersen-treated adult SMA patients at different treatment time points compared to non-treated adult SMA patients [F(2.93,69.59) = 3.212, p = 0.03]. This evidence concerns the gene CHI3L1 and proximal spinal muscular atrophy.